Study design of a randomised, placebo-controlled trial of nintedanib in children and adolescents with fibrosing interstitial lung disease

Childhood interstitial lung disease (chILD) comprises >200 rare respiratory disorders, with no currently approved therapies and variable prognosis. Nintedanib reduces the rate of forced vital capacity (FVC) decline in adults with progressive fibrosing interstitial lung diseases (ILDs). We present...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :ERJ Open Res
Главные авторы: Deterding, Robin, Griese, Matthias, Deutsch, Gail, Warburton, David, DeBoer, Emily M., Cunningham, Steven, Clement, Annick, Schwerk, Nicolaus, Flaherty, Kevin R., Brown, Kevin K., Voss, Florian, Schmid, Ulrike, Schlenker-Herceg, Rozsa, Verri, Daniela, Dumistracel, Mihaela, Schiwek, Marilisa, Stowasser, Susanne, Tetzlaff, Kay, Clerisme-Beaty, Emmanuelle, Young, Lisa R.
Формат: Artigo
Язык:Inglês
Опубликовано: European Respiratory Society 2021
Предметы:
Study Protocols
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8215331/
https://ncbi.nlm.nih.gov/pubmed/34164554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1183/23120541.00805-2020
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы